The roles of IFNγ in protection against tumor development and cancer immunoediting

By H. Ikeda, Lloyd J. Old, Robert Schreiber. 2002

769 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a94196c440ed5e95bb8387c8ef5aa11fc3af89ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. H. Yanai
2. Michel Sadelain
3. A. Takaoka
4. Shizuo Akira
5. Taro Kawai
6. R. Medzhitov
7. O. Takeuchi

In Oncology

1. Michel Sadelain
2. A. Takaoka
3. H. Yanai
4. James J. Collins
5. Wilson W. Wong
6. Jang-Hwan Cho

Citations in the corpus

• Interferon signalling network in innate defence (2006, background): “Type II IFN Type II IFN comprises solely IFN-γ (Bach et al., 1997; Pestka, 1997; Ikeda et al., 2002) (Table 1), which similarly has antiviral activity.”
• Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015, positive): “…anti-tumor effects of IFNg are well documented, including direct anti-proliferative and pro-apoptotic effects on tumor cells (Chin et al., 1996; Ikeda et al., 2002), targeting of the tumor microenvironment through inhibition of angiogenesis (Ikeda et al., 2002), and stimulation of the innate…”